Tsoong induces apoptosis and inhibits proliferation, migration and invasion of pancreatic ductal adenocarcinoma cells.

The roots of Codonopsis cordifolioidea (classified as campanulaceae cordifolioidea), locally known as Tsoong, have been used as a tonic food. The major components isolated from Tsoong have been demonstrated to present anti‑human immunodeficiency virus‑1 activities and cytotoxicity against various tumor cell lines. However, the possible effects of the novel compound isolated from Tsoong, cordifoliketones A, on pancreatic ductal adenocarcinoma (PDAC) cells, are still unknown. In the present study, cordifoliketones A extractions were prepared from Tsoong, and the possible effects on PDAC cell growth, apoptosis, migration and invasion in vitro and in vivo were exlored. The cytotoxicity assay, apoptosis assay, western blotting, migration and invasion assay, and a PDAC cell (AsPC‑1, BxPC‑3 and PANC‑1) xenograft mice model were employed. The results demonstrated that treatment with cordifoliketones A: i) inhibited proliferation and promoted apoptosis of PDAC cells; ii) significantly induced apoptosis and altered expression of apoptosis‑associated proteins in a dose‑dependent manner; iii) suppressed migration and invasion of PDAC cells in a dose‑dependent manner; and iv) restrained the growth of PDAC neoplasm in nude mice. Furthermore, cordifoliketones A demonstrated non‑cytotoxic activity in a panel of normal human cells, including hTERT‑HPNE, 293, hepatocyte HL‑7702 and HL‑1 cells. Therefore, these data indicated that cordifoliketones A may be a potential candidate compound for the prevention of PDAC cell proliferation and metastasis, presumably by induction apoptosis and inhibiting viability, invasion and migration of PDAC cells.

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic neoplasm, and is highly aggressive and malignant with a very low survival rate. Nowadays, as a devastating disease, PDAC is the fourth most common disease-associated mortality worldwide (1,2). The 5-year survival rate is ~6%, and only 20% of patients present with resectable disease (3,4). The high mortality of these patients is partly due to more than three-quarters of the cases being diagnosed at too late a stage to allow surgical resection, which is the only curative option. Non-surgical patients are treated with standard chemotherapies (5). Despite numerous promising novel therapies approved by the Food and Drugs Administration, the advances have been very slow for patients with PDAC (6). In addition, some cancer cells can become progressively resistant to drugs during the course of treatment, ultimately resulting in a non-responsive tumor to chemotherapies (7). Therefore, novel effective therapeutic methods are necessary.

Traditional Chinese medicine is appreciated for its 5000-year-old history and still holds an important position in primary health care in China; it has also become more popular among cancer patients in the western world (8). Recent reports also demonstrated that Chinese herbs may be used for the development of functional foods, the promotion of health, and as pharmaceutical agents for various kinds of human cancers, such as oral, gastric, breast and epithelial ovarian cancers (9–13).

Codonopsis (Campanulaceae, C.) is represented in China by 39 species, some of which are commonly used as herbal remedies due to their tonic effects, such as C. pilosula and C. tangshen (14). In addition, the roots of some Codonopsis species, including C. cordifolioidea, C. bulleyana, C. micrantha and C. subglobosa, are well-known vegetables in southwest China (15,16). Codonopsis cordifolioidea (C. cordifolioidea) is herbaceous plant found in Yunnan, Tibet, and Sichuan Provinces. Its roots, locally known as Tsoong, have been used as a food in Yunnan Province since ancient times (13). Meanwhile, this species has become an important economic plant widely cultivated in several areas of Yunnan Province (17,18). As major components isolated from C. cordifolioidea, phenylpropanoids, lignans and flavonoids are isolated and demonstrated to present biological effects of anti-human immunodeficiency virus type 1 (HIV-1) activities and cytotoxicity (13,19). Hu et al (13) have performed and finished the isolation, structural elucidation and biological activities assessing of the major compounds, termed cordifoliketones A-B. The cytotoxicity tests for the isolates were performed in HL-60 (human acute promyelocytic leukemia), Hep-G2 (human hepatocellular carcinoma), KB (human oropharyngeal epidermoid carcinoma) and MDA-MB-231 (human breast cancer cells) tumor cell lines. Their results revealed that compounds 1–2 have significant potential cytotoxic abilities against various tumor cell lines (13). However, the possible effects of these new compounds isolated from the roots of C. cordifolioidea, Tsoong, on the proliferation, apoptosis, migration and invasion ability of PDAC, are still unknown.

In present study, an extraction of cordifoliketones A from Tsoong was prepared, and the possible effects against PDAC cells was explored. The human PDAC cell lines, AsPC-1, BxPC-3 and PANC-1, were used. The cytotoxicity against PDAC cells and the effects of cordifoliketones A on PDAC cell proliferation, apoptosis, invasion and migration were examined in vitro and in vivo. The effect of cordifoliketones A treatment on the survival and apoptosis, invasion and migration of human PDAC cell in vitro, were evaluated by resazurin reduction assay, flow cytometry, and migration and invasion assays. Western blotting was also used to determine the expression of cytokine associated with apoptosis. A xenograft nude mouse model was established by injection with PDAC cells followed by treatment with cordifoliketones A.

On day 27 post treatment, mice were sacrificed, and tumors were isolated for determination of weight and volume.

Materials and methods

Preparation of cordifoliketones A

Tsoong, roots of C. cordifolioidea, were collected in Dali Prefecture and Yuxi (Yunnan, China) in September 2013. The identification of the plant material was verified by Professors Chen. and Mei (Yunnan Nationalities University). A voucher specimen (YNNI 09-9-13) was used. The air-dried and powdered roots of C. cordifolioidea (1.5 kg) were repeatedly subjected to column chromatography on Si gel, Sephadex LH-20, RP-18 and Preparative high-performance liquid chromatography systems to obtain a 70% aqueous methanol extract, which contained compounds 1–11, including two novel phenylpropanoids, termed cordifoliketones A-B, together with nine known phenylpropanoids (13). The combined extract was then stepwise eluted by petroleum, ethyl acetate and n-butyl alcohol (20). A total of 50 mg phenylpropanoids, termed cordifoliketones A, was isolated and extracted by vacuum column chromatography at 20–25°C. The combined phenylpropanoids were subjected to a silica gel (Merck KGaA, Darmstadt, Germany) vacuum liquid chromatography and eluted with n-hexane (Sigma-Aldrich; Merck KGaA; diameter, 6.5 cm), chloroform (Sigma-Aldrich; Merck KGaA), EtOAc (Sigma-Aldrich; Merck KGaA), acetone (Sigma-Aldrich; Merck KGaA) and MeOH (Sigma-Aldrich; Merck KGaA) to obtain a major product. The product was then subjected to silica gel open column chromatography (diameter, 5 cm) and eluted with n-hexane-EtOAc step gradients. Following this, 23 fractions of 200 ml each were collected. These fractions were then pooled into eleven new fractions (compounds 1–11). Nine of them were known phenylpropanoids as described previously (13). The novel phenylpropanoid, was crystallized from n-hexane to obtain colorless crystals and termed as cordifoliketones A. The physicochemical data cordifoliketone A are presented in Fig. 1A and described as followed: Obtained as pale yellow gum; UV (MeOH) λmax (log ε) 325 (2.42), 288 (4.22), 248 (3.12), 210 (4.89) nm; IR (KBr) νmax 3376, 2925, 2850, 1713, 1638, 1512, 1450, 1434, 1362, 1283, 1175, 1137, 1086, 1047, 971, 828 cm-1; 1H and 13C NMR data (C5D5N, 500 and 125 MHz, respectively); positive ESIMS m/z 249 [M+Na]+; HRESIMS m/z 249.0746 [M+Na]+ (calculated 249.0739 for molecular formula determined as C11H14NaO5). The cordifoliketones A was prepared and dissolved in 0.2% ethanol (v/v) in the present study.

Figure 1.

Cordifoliketones A inhibits proliferation of different PDAC cell lines. (A) The structure of cordifoliketones A extracted from the roots of C. cordifolioidea, Tsoong. -Ac, acetyl (CH3CO-). (B) Dose effect of cordifoliketones A treatment on the proliferation of three PDAC cell lines (AsPC1, BxPC-3 and PANC-1), and normal human cell lines. The cell number at each cordifoliketones A concentration is represented as a percentage of control. Average values are from three independent experiments performed in six replicates. (C) Fluorescence signal screening assay in cells treated with different doses of cordifoliketones A. Data are presented as the mean ± standard deviation (n=3). #P<0.05 vs. hTERT-HPNE; ##P<0.05 vs. HL-7720 cells; **P<0.05 vs. HL-1 cells; *P<0.05 vs. 293 cells. PDAC, pancreatic ductal adenocarcinoma.

Cell culture

Human PDAC cell lines AsPC-1, BxPC-3 and PANC-1, the hTERT-HPNE and 293 normal human pancreatic cells, the HL-7702 hepatocyte cell line, and HL-1 cardiac myocytes were purchased from Cell Bank of the Chinese Academy of Sciences (Shanghai, China). PDAC cell lines and hTERT-HPNE cells were cultured in specific medium supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% antibiotics at 37°C in a humidified incubator under 5% CO2 (3). The HL-7702 cells were cultured in RPMI 1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 8% dialyzed FBS (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin (Gibco; Thermo Fisher Scientific, Inc.) as described previously (21). HL-1 cells were cultured in Claycomb medium supplemented with 10% FBS, 2 mM L-glutamine, 0.1 mM norepinephrine, 100 units/ml penicillin and 100 µg/ml streptomycin. The cells were cultured at 37°C and 5% CO2. Twice a week, cells were split after reaching confluence. 293a cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% FBS, 1% L-glutamine and 1% penicillin-streptomycin stock solutions. All of the cells were negative for: HIV-1, hepatitis B virus, hepatitis C virus as detected by quantitative polymerase chain reaction; mycoplasma using fluorescent monoclonal antibodies against major outer membrane protein; bacteria under microscopy without in medium antibiotics and varying pH values, yeast and fungi with a lack of hyphae with microscopy prior to experimentation by the Cell Bank of the Chinese Academy of Sciences (Shanghai, China).

Cytotoxicity assay

Resazurin reduction assay was performed to test the cytotoxic effects of the natural product, cordifoliketone A, on three PDAC cell lines (AsPC-1, BxPC-3 and PANC-1) and normal human cells (hTERT-HPNE, HL-7702, HL-1 and 293 cells) as described before (22,23). The contribution of the extracts (at various tested concentrations, including 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5 and 6 µmol/ml, respectively) to the fluorescence (Fs) was determined, both in the absence and presence of resazurin, prior to any cell studies. A total of 2×104 cells/well were seeded in 96-well plates in a total volume of 100 µl. Cordifoliketone A of varying concentrations (0–6 µmol/ml) or the positive control Doxorubicin (3.5 µmol/ml), was immediately added to additional 100 ml of culture medium to obtain a total volume of 200 µl/well, respectively. After 24 h or 48 h, 20 ml resazurin (Sigma-Aldrich, Merck KGaA) 0.01% w/v in ddH2O was added to each well and the plates were incubated at 37°C for 4 h. Blank control were treated with 20 µl ddH2O instead of resazurin. Fluorescence was measured on a microplate reader using an excitation wavelength of 544 nm and an emission wavelength of 590 nm. Doxorubicin was used as positive control. After 72 h incubation and staining by resazurin (Sigma-Aldrich, Merck KGaA), Fs was measured on a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, United States) using an excitation wavelength of 544 nm and an emission wavelength of 590 nm. Each assay was performed at least three times, with six replicates each. Half-maximal inhibitory concentration (IC50) values represent the sample concentration required to inhibit 50% of cell proliferation, and was calculated from a calibration curve by linear regression as described previously (24). The calculation formula was as follows: Percentage (%) of cell proliferation=(Fs of cells treated with cordifoliketone A/Fs of untreated cells) ×100.

Apoptosis assay

A propidium iodide (PI) and Annexin V-fluorescein isothiocyanate-flow cytometry assay (BD Pharmingen; BD Biosciences, Franklin Lakes, NJ, USA) was used to detect the apoptosis rate in the AsPC-1, BxPC-3 and PANC-1 cells after treatment with various concentrations of cordifoliketones A (0, 2, 4 or 6 µg/ml). In the 0 µmol/ml cordifoliketones A group, cells were treated with 0.2% ethanol. Briefly, 1×106 cells per well were cultured in 6-well plates in the absence of 10% FBS for 48 h. Adherent cells were detached with 0.25% trypsin without EDTA in 1X PBS. Cells were harvested in complete RPMI 1640 medium and centrifuged at 350 × g for 5 min. According to the manufacturer's protocol, each of the cells were washed with 1X PBS and then stained with 50 ug/ml PI and Annexin V-FITC at 25°C for 30 min (25).

Detection of apoptosis-associated proteins by western blotting

The present study used western blotting to evaluate the protein expression levels of caspase-3, caspase-8, caspase-9, Bad, Bax, Bcl-2 and Bcl-xL in PDAC cell lines. Antibodies for caspase-3 (sc-271759), caspase-8 (sc-5263), caspase-9 (sc-17784), Bad (sc-8044), Bax (sc-20067), Bcl-2 (sc-509), Bcl-xL (sc-136207) and GAPDH (sc-69778) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). According to the manufacturer's protocols, ~40 mg total cell lysate protein [quantified with a Bicinchoinic Acid Protein Assay kit (Beyotime Institute of Biotechnology, Shanghai, China)] extracts from each cell line were separated using 15% SDS-PAGE and transferred to nitrocellulose membranes (Beyotime Institute of Biotechnology). The membrane was blocked with PBS containing 0.05% Tween-20 (PBST; (Beyotime Institute of Biotechnology,) with 10% nonfat dry milk (Beyotime Institute of Biotechnology) overnight at 4°C for 12 h and subsequently washed three times for 10 min each time. The membrane was incubated with monoclonal anti-Bax (1:500), anti-Bcl-2 (1:200), anti-Bcl-xL (1:800), anti-Bad (1:800), and polyclonal anti-caspase-3 (1:1,000), −8 (1:200), and −9 (1:500) antibodies at 4°C for 24 h. Following three washes three times for 10 min each, the membrane was incubated with a horseradish-peroxidase conjugated rabbit anti-mouse IgG (1:2,500; Beyotime Institute of Biotechnology, A0216) for 2 h at room temperature, and washing three times for 10 min each time. Then the membrane was developed in enhanced chemiluminescence-based detection (GE Healthcare, Chicago, IL, USA) as previously described (25). The optical densities of the protein bands for the target proteins were analyzed for each group in order to semi-quantity the protein levels (26,27).

Cell migration and invasion assay

The present study determined the possible effect of cordifoliketones A on the viability of PDAC cells. Following this, the effect of cordifoliketones A on proliferation of PDAC cells in vivo was also detected. BioCoat Matrigel invasion chambers (BD Biosciences) were used to compare the effect of cordifoliketones A treatment on in vitro invasion of AsPC-1, BxPC-3 and PANC-1 cells, according to the manufacturer's protocol. Briefly, for the invasion assay, Costar Transwell 8-µm inserts were coated with 50 µg reduced serum Matrigel (BD Biosciences). Invasion chambers were coated with Matrigel. AsPC-1, BxPC-3 and PANC-1 cells (1×106) were treated with various concentrations of cordifoliketones A (0.2% ethanol): 0, 2, 4 or 6 µg/ml were added per chamber.

Dulbecco's modified Eagle's medium (BD Biosciences) supplemented with 10% FBS was used in the lower chamber. Following incubation, the cells that had invaded through the membrane were fixed with polyoxymethylene at 25°C for 30 min (Sigma-Aldrich, Merck KGaA) and stained with crystal violet (Sigma-Aldrich, Merck KGaA), at room temperature for 0.5 h, before the membrane was removed and mounted on a slide for microscopic assessment. Invasive cells were visualized at ×40 magnification under a light microscope (Leica Microsystems GmbH, Wetzlar, Germany) and the number of cells in five random fields was counted and the average calculated (average=sum number of cells in five random fields/five). For migration assays, the same procedure was used excluding the Matrigel.

After 12 h, non-invading cells and media were removed, and cells on the lower surface of the membrane were fixed with polyoxymethylene and stained with 0.1% crystal violet (both from Sigma-Aldrich; Merck KGaA) for 0.5 h at room temperature. Stained cells were counted under a microscope (Leica Microsystems GmbH, inverted microscope, DMI3000B) in five randomly selected fields, and the aforementioned average (as described above) was used to indicate cell migration and invasion. All experiments were performed in triplicate (8).

PDAC cells xenograft mouse model

A total of 36 BALB/c nude mice (female; age, 4–5 weeks; weight, 20–25 g; Beijing HFK Bioscience Co., Ltd., Beijing, China; animal license no. SCXK 2009–000) were housed and raised in the laboratory animal center of Yunnan University (Kunming, China). The mice were maintained in a 20–25°C quiet, 40–60% humidified vivarium under a 12 h light/dark cycle. They were allowed free access to water and food prior to experimentation. The treatment and use of animals during the study was approved by the Animal Ethics Committee of Yunnan University.

Mice were randomly assigned to 6 groups (n=6/group): Mice bearing human AsPC-1, BxPC-3 and PANC-1 cells alone (PDAC + placebo groups, control), as well as mice bearing human AsPC-1, BxPC-3 and PANC-1 cells and treatment with cordifoliketones A (PDAC + CA groups). In a preliminary experiment, different concentrations (20, 80, 120, and 240 M/kg) of cordifoliketones A (ethanol extract, 80 M, supplied by Prof. Yu-Ming Chen of Shanghai Traditional Medical University, Shanghai, China) were used to assess the appropriate in vivo dose. IC50 values of cordifoliketones A in PANC-1 cells were the highest among the three PDAC cell lines in vitro. A volume of 100 µl of PANC-1 cells suspended in PBS (1.0×107/ml) were injected intradermally into the left axilla of the mice. On the following day, mice bearing PDAC-1 cells received 20, 80, 120 or 240 M/kg cordifoliketones A or an equal volume noncytotoxic placebo (0.2% ethanol) treatment by gavage once a day. Following seeding, liquid absorption at the injection site, tumor growth (volume and weight), as well as mouse condition, status and survival were observed. Tumor volume was measured on days 5, 7, 12, 16, 19, 21, 25 and 27 post-injection. A concentration of 240 M/kg was used for subsequent experiments the most prominent effects in tumor growth inhibition. A volume of 100 µl of each cell type suspended in PBS (1.0×107/ml) was injected intradermally into the left axilla of the mice. On the following day, mice bearing PDAC cells received 240 M/kg cordifoliketones A or an equal volume 0.2% ethanol (noncytotoxic placebo) treatment by gavage once a day. After seeding, liquid absorption at the injection site, tumor growth (volume and weight), and mouse survival were observed. Tumor volume was measured on days 5, 7, 12, 16, 19, 21, 25 and 27 post-injection. On day 27, all mice were sacrificed, and tumors were isolated for determination of weight and volume (28).

The largest (a) and smallest diameters (b) of each tumor were measured twice on days 5, 7, 12, 16, 19, 21, 25 and 27 to estimate tumor volume (V) using the formula V=0.52 × a2 × b (31). Mean tumor volumes were used to plot tumor growth curves for each group of mice.

Statistical analysis

SPSS v13.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Data are presented as means ± standard deviation. One-way analysis of variance with five levels was used with a completely randomized design, and the homogeneity of variance was tested. A q test (Student-Newman-Keuls) was used to compare the differences between groups, and a rank sum test was performed to randomly compare treatments. P<0.05 was considered to indicate a statistically significant difference.

Results

Cytotoxic of cordifoliketones A on PDAC cells

The cytotoxic abilities against AsPC-1, BxPC-3, PANC-1 and normal human cells by resazurin reduction assay (with doxorubicin as the positive control) are presented in Table I. The structure of cordifoliketones A extracted from the roots of C. cordifolioidea is presented in Fig. 1A. The results demonstrated that cordifoliketones A has significant potential cytotoxic abilities against various PDAC cell lines in a dose-dependent manner, with IC50 values ranging from 4.18 to 5.56 µg/ml (Table I). The lowest IC50 value of 4.18 µg/ml was obtained by treating PANC-1 cells with cordifoliketones A. Compared to with PDAC cells, normal human hTERT-HPNE cells, and 293, HL-7702 and HL-1 cells were relatively resistant to cordifoliketones A (IC50 was >6 µg/ml, the highest concentration tested in the study), which implies the specific anticancer activities of cordifoliketones A (Fig. 1B and C). Treatment with cordifoliketones A (>3 µg/ml) revealed a significant inhibition in cell viability of PDAC cells. In addition, cordifoliketones A significantly reduced the resazurin fluorescence values from 3–6 µg/ml.

Table I.

Cytotoxic effects of compounds on a variety of pancreatic ductal adenocarcinoma cells.

	PDAC cell lines (IC50 µg/ml)
Compounds	AsPC-1	BxPC-3	PANC-1
Cordifoliketones A	5.56±0.22	4.26±0.11	4.18±0.31
Doxorubicin (µM)	2.86±0.21	2.69±0.14	3.49±0.18

Values were expressed as means ± standard deviation (n=3).

Cordifoliketones A treatment induces apoptosis of PDAC cells

In the three types of PDAC cells, there was a significant increase in the apoptosis rate after treatment with 2 µg/ml cordifoliketones A, compared with 0 µg/ml (blank control; Fig. 2). In AsPC-1, BxPC-3 or PANC-1 cells, cordifoliketones A increased the apoptosis rate in a dose-dependent manner. There were more apoptotic PDAC cells in the 6 µg/ml cordifoliketones A-treated groups, when compared with that the 2 and 4 µg/ml treated groups, respectively (P<0.05, Fig. 2). However, cordifoliketones A exhibited no significant effects on the apoptosis of normal human cell lines (Fig. 2C, P>0.05).

Figure 2.

Treatment with cordifoliketones A induces apoptosis in PDAC cells. AsPC-1 cells, BxPC-3, PANC-1 and normal human cells were treated with cordifoliketones A at various doses. (A) The effect of cordifoliketones A (0, 2, 4 and 6 µg/ml) on the apoptosis of AsPC-1, BxPC-3 and PANC-1 cells were detected by flow cytometry. (B) Quantification demonstrated that the percentage of apoptotic cells in cordifoliketones A-treated cells was significantly higher compared with the control group (0 µg/ml) in a dose-dependent manner. (C) Cordifoliketones A had no effect on apoptosis in normal human cell lines. Average values are from three independent experiments performed in duplicate. Data are presented as the mean ± standard deviation (n=3). PDAC, pancreatic ductal adenocarcinoma; FITC, fluorescein isothiocyanate; PI, propidium iodide.

Effects of cordifoliketones A on the expression of apoptosis-associated proteins

Quantitative analysis by western blotting demonstrated that cordifoliketones A upregulated the expression of Bax and Bad, and down-regulated the expression of Bcl-2 and Bcl-xL in AsPC-1 (Fig. 3), BxPC-3 (Fig. 4) and PANC-1 (Fig. 5) cells in a dose-dependent manner (P<0.05). For the other apoptosis-associated proteins tested, caspase-3/8/9 expression were significantly upregulated after treatment with 2, 4 or 6 µg/ml cordifoliketones A in AsPC-1, BxPC-3 and PANC-1 cells (P<0.05, Figs. 3, 4 and 5, respectively).

Figure 3.

Cordifoliketones A affects the expression of apoptosis-associated proteins in AsPC-1 cells. (A) Representative western blot images and (B) quantification of protein expression levels of Bax, Bad, Bcl-xL, Bcl-2, caspase-3, caspase-8 and caspase-9 following cordifoliketones A treatment (0, 2, 4, and 6 µg/ml). Average values are from three independent experiments performed in duplicate. Data are presented as the mean ± standard deviation (n=3). Bax, Bcl-2-associated X protein; Bad, Bcl-2-associated death promoter; Bcl-XL, B-cell lymphoma extra-large; Bcl-2, B-cell lymphoma 2.

Figure 4.

Cordifoliketones A affects the expression of apoptosis-associated proteins in BxPC-3 cells. (A) Representative western blot images and (B) quantification of protein expression levels of Bax, Bad, Bcl-xL, Bcl-2, caspase-3, caspase-8 and caspase-9 following cordifoliketones A treatment (0, 2, 4, and 6 µg/ml). Average values are from three independent experiments performed in duplicate. Data are presented as the mean ± standard deviation (n=3). Bax, Bcl-2-associated X protein; Bad, Bcl-2-associated death promoter; Bcl-XL, B-cell lymphoma extra-large; Bcl-2, B-cell lymphoma 2.

Figure 5.

Cordifoliketones A affects the expression of apoptosis-associated proteins in PANC-1 cells. (A) Representative western blot images and (B) quantification of protein expression levels of Bax, Bad, Bcl-xL, Bcl-2, caspase-3, caspase-8 and caspase-9 following cordifoliketones A treatment (0, 2, 4, and 6 µg/ml). Average values are from three independent experiments performed in duplicate. Data are presented as the mean ± standard deviation (n=3). Bax, Bcl-2-associated X protein; Bad, Bcl-2-associated death promoter; Bcl-XL, B-cell lymphoma extra-large; Bcl-2, B-cell lymphoma 2.

Cordifoliketones A inhibits migration and invasion of PDAC cells

Following treatment with cordifoliketones A at 2, 4 or 6 µg/ml, there were significant reductions in the invasion of AsPC-1, BxPC-3 and PANC-1 cells, in comparison with that of the control cells (treated with 0 µg/ml; P<0.05; Fig. 6). Furthermore, cordifoliketones A induced inhibitions in migration and invasion of PDAC cells in a dose-dependent manner (Fig. 6).

Figure 6.

Effects of cordifoliketones A treatment on the migration and invasion of PDAC cell lines and normal human cells. (A) Invasion and (B) migration of PDAC cells. (C) Invasion and (D) migration of normal human cells. Invasion is expressed as number of invading cells per 40× field. Average values are from three independent experiments performed in duplicate. Data are presented as the mean ± standard deviation (n=3). PDAC, pancreatic ductal adenocarcinoma.

Cordifoliketones A treatment inhibits the proliferation of PDAC in vivo

To explore the efficacy of cordifoliketones A against PDAC in vivo, the xenograft models were established via subcutaneous injection of cells, and tumor growth was monitored. On day 27 post-injection, mice were sacrificed and the tumors were dissected and weighed. Neoplasms in cordifoliketones A-treated mice grew much more slowly than that in control mice (Fig. 7).

Figure 7.

Cordifoliketones A treatment inhibits tumor formation and growth in nude mice. (A) Mice were imaged on day 27. (B) Image of representative tumors. (C) Growth of tumors over 27 days. #P<0.05 vs. AsPC-1 group; **P<0.05 vs. BxPC-3 group; *P<0.05 vs. PANC-1 group. (D) Weight of tumors. #P<0.05 vs. AsPC-1 group; *P<0.05 vs. BxPC-3 group; **P<0.05 vs. PANC-1 group. Data are presented as the mean ± standard deviation (n=6). CA, treatment with cordifoliketones A; PDAC, pancreatic ductal adenocarcinoma.

Discussion

In present study, cordifoliketones A was extracted from the roots of C. cordifolioidea, Tsoong. The effects of cordifoliketones A on tumor cell growth, apoptosis, invasion, and migration were examined. The data demonstrated that cordifoliketones A: i) inhibited proliferation and promoted apoptosis of PDAC cells without cytotoxicity against to normal human cells; ii) significantly induced apoptosis and altered expression of apoptosis-associated proteins in a dose-dependent manner; iii) suppressed migration and invasion of PDAC cells in a dose-dependent manner; and iv) restrained the growth of PDAC neoplasms in nude mice. Therefore, these results indicate that cordifoliketones A may be a potential candidate compound for the prevention of PDAC proliferation and metastasis.

Natural products have been used in traditional and folk medicine for therapeutic purposes. They are generally nontoxic compared to synthetic chemical compounds, and thus provide important sources of promising leads for the development of novel therapeutic drugs (30). In this regard, the search for novel chemopreventive and anti-tumor agents that are more effective and less toxic has created a great deal of interest in phytochemicals (30). The roots of C. cordifolioidea, locally known as Tsoong, have been used as a food or vegetable and herbal remedies due to their tonic effects in Yunnan Province since ancient times (17,30). Recently, phytochemical research also revealed that the crude extract of Tsoong increased the chemotherapeutic sensitivities, and attenuated and enhance immune function of tumor-bearing mice (31). In light of this, the major components from this plant were isolated and identified. In particular, cordifoliketones A, as one of compounds of the roots of Tsoong, was isolated and demonstrated to have anti-HIV and cytotoxic properties (13). The present study demonstrated that the cytotoxic properties against PDAC cells of cordifoliketones A might be associated with apoptosis promotion and proliferation inhibition.

Disordered apoptosis is important in many disease processes, including oncologic and rheumatologic phenomena, and thus the accurate control of apoptosis is important not just to the normal development of an organism, but also to its health and growth (32). Therefore, various kinds of agents that can effectively induce apoptosis offer promising strategies for the treatment of cancer. The present study revealed that treatment with cordifoliketones A significantly induced apoptosis and altered the expression of apoptosis-associated proteins in a dose-dependent manner in PDAC cells. Cordifoliketones A was cytotoxic to AsPC-1, BxPC-3 and PANC-1 cells with an IC50 at most of 5.56 µmol/ml (Table I). This cytotoxicity may be attributable to the induction of apoptosis, as demonstrated by an apoptosis assay and expressional evaluation of proteins associated with apoptosis. The Ced-3/caspase-1 family, which is comprised of caspase-1, caspase-2, caspase-3, caspase-4, caspase-6, caspase-7, caspase-9 and caspase-10, functions as a key component of apoptosis, and acts to destroy specific target proteins which are critical to cellular longevity (33). As an initiator caspase, caspase-8 activates effector caspases by cleaving their inactive forms. In the activation cascade responsible for apoptosis induced by tumor necrosis factor receptor superfamily member 1A and mediated by tumor necrosis factor receptor superfamily member 6, caspase-8 is the most upstream protease. B-cell lymphoma 2 (Bcl-2) among numerous key regulators of apoptosis, are essential for development, tissue homeostasis and protection against foreign pathogens. Human Bcl-2 is an anti-apoptotic, membrane-associated oncoprotein that can promote cell survival via protein-protein interactions with other Bcl-2-associated family members, such as the death suppressors B-cell lymphoma extra-large (Bcl-xL), induced myeloid leukemia cell differentiation protein (MCL-1), Bcl-2-like protein 2 and A1, or the death agonists Bcl-2-associated X protein (Bax), Bcl-2 homologous antagonist/kiler, Bcl-2 interacting killer, Bcl-2-associated death promoter (Bad) and BH3-interacting domain death agonist (33,34).

Cordifoliketones A upregulated the expression of Bax, Bad and caspase-3/8/9, and downregulated the expression of Bcl-2 and Bcl-xL. As a complex biochemistry process, apoptosis is regulated by a variety of factors (35,36). The two most important groups of proteins involved in apoptotic cell death has been demonstrated as members of the Bcl-2 family and caspases (37,38). It is well known that the Bcl-2 family functions as inhibitors (e.g. Bcl-2, Bcl-xL and MCL-1) or promoting factors (e.g. Bax, Bcl-XS, Bad and Bak) in programmed cell death, apoptosis. Otherwise, subsequent activation of caspase-3 has been regarded as a primary mechanism of apoptosis (38,39). Given this knowledge, it was hypothesized that cytotoxic properties against PDAC cells of cordifoliketones A might be associated with induction apoptosis. Additionally, chemical agents with strong apoptosis-inducing activity but minimal toxicity are expected to have potential utility as anticancer drugs (22,40). The present study additionally revealed that cordifoliketones A exhibited no cytotoxicity to normal hTERT-HPNE cells, which suggested that cordifoliketones A might be a promising anticancer drug against PDAC. Furthermore, the present data also demonstrated that cordifoliketones A treatment cells inhibited the migration and invasion of PDAC cells in a dose-dependent manner. Therefore, the results indicated that cordifoliketones A might prevent of PDAC metastasis by inhibiting in invasion and migration.

Taking together, these results indicate that cordifoliketones A may be a potential candidate compound for the prevention of PDAC proliferation and metastasis, presumably by induction apoptosis, inhibiting proliferation, invasion and migration of PDAC cells, as well as minimal toxicity to normal cells. However, the mechanisms underlying remain unknown and require further investigation.

In conclusion, the present study demonstrated that cordifoliketones A prepared from the roots of C. cordifolioidea, Tsoong: i) inhibited proliferation and promoted apoptosis of PDAC cells; ii) significantly induced apoptosis and altered expression of apoptosis related protein in a dose-dependent manner; iii) suppressed migration and invasion of PDAC cells in a dose-dependent manner; and iv) restrained the growth of PDAC neoplasm in nude mouse. Furthermore, cordifoliketones A exhibited non-cytotoxic activity in normal human cells. Therefore, these results indicated that cordifoliketones A may be a potential candidate compound for the prevention of PDAC proliferation and metastasis, presumably by induction of apoptosis, and inhibiting invasion and migration of PDAC cells.